The global co-manufacturing market reached USD 686 billion in 2025 and is projected to hit USD 969 billion by 2030, with North America accounting for USD 64.5 billion. Co-manufacturing (or contract manufacturing) is a model where a company outsources the production of its products to specialized industrial plants. This guide explains how to transition from in-house production to external manufacturing—or launch new products through industrial partners.
1. Categories of industrial outsourcing
Choosing the right partner defines how much control you retain over your supply chain and formulation:
- Contract manufacturing (co-manufacturing): The manufacturer produces the full product according to your specifications. For example, General Mills worked with 200 co-manufacturers during the pandemic to expand capacity but later reduced partnerships due to rising freight costs. Here, the manufacturer buys ingredients and packaging, simplifying your logistics.
- Toll manufacturing: You provide all raw materials and packaging. The manufacturer charges a processing fee for labor and equipment. Best suited when you have proprietary ingredients or exclusive supplier agreements.
- Co-packing: Focused on filling and labeling. Used when bulk product is made in one facility and shipped to another for final packaging. Maryland Packaging, for instance, offers co-packing with HPP (high-pressure pasteurization) for fresh products.
- Private label: The manufacturer uses its own formula and applies your brand label. Examples include Walmart’s Great Value, Whole Foods’ 365, and Target’s Good & Gather. Fastest route to market, but with less differentiation.
2. Financial analysis CAPEX vs. OPEX
Fixed costs eliminated (CAPEX):
No need to invest in land, factories, or machinery. Capital can be redirected to marketing, R&D, and commercial expansion. During the pandemic, pharma and biotech companies leaned heavily on CMOs to meet demand without building new plants.
Variable costs integrated (OPEX)
Production costs become per-unit operating expenses. This makes COGS easier to calculate and shields margins from labor or maintenance fluctuations, since risks are transferred to the manufacturer. However, General Mills’ CFO warned that freight costs can spiral when combined with rising ingredient, packaging, energy, and transport expenses. The decision must weigh capex savings against logistics inflation.
3. Selection criteria and technical audits
Equipment compatibility:
Quality standards & certifications:
Look for internationally recognized certifications:
- SQF or BRC (essential for major retailers)
- HACCP (hazard analysis and critical control points)
- Specialized certifications (organic, kosher, halal, non-GMO)
Samsung Biologics, for example, implemented full digital connectivity and AI-driven services to enhance production quality.
MOQ flexibility
Minimum order quantity defines financial feasibility. Typical ranges:
- 1,000–2,000 units per SKU for general products
- 1,000–20,000 units for beverages, depending on packaging format
High MOQs risk excess inventory and storage costs, while very low MOQs may make unit costs unviable due to setup time.
4. Implementation process: from RFP to full-scale production
- RFP (request for proposal): Detail forecasted volumes, ingredient specs, and packaging requirements. Include pH/°Brix/ABV targets, carbonation levels, and packaging formats.
- Bench tests & sampling: Small-scale samples validate formula performance on industrial equipment.
- Line trial: Limited production run to identify bottlenecks and adjust temperature, speed, and pressure.
- Pilot batch: First commercial batch for shelf-life testing and final quality validation.
- Full-scale production: Ramp up to meet demand. Lonza, for instance, expanded U.S. biologics capacity in 2024 to serve mid-to-large bio-pharma clients.
5. Risk mitigation & intellectual property
Legal safeguards protect intangible assets:
- NDAs (non-disclosure agreements): Must be airtight to prevent formula leaks. In most cases, leaked information cannot be patented. In Europe, patents may still be filed within 6 months if violation evidence exists.
- Non-use & non-circumvention clauses: Prevent manufacturers from developing competing products or approaching your clients directly.
- Formula ownership: Contracts should guarantee that IP developed jointly belongs to the brand owner.
- SLAs (service level agreements): Define delivery timelines, raw material loss rates, and defect rejection criteria. Samsung Biologics secured over USD 3.3 billion in new contracts in 2024, underscoring the importance of strong agreements.
6. Smart sourcing & technology
Forget manual trade shows — digital platforms accelerate sourcing:
- Specialty filters: Find plants focused on niches like energy drinks or plant-based snacks.
- Capacity transparency: With reshoring under USMCA, 350,000 jobs moved to Mexico in 2024. Identifying plants with idle capacity is critical for urgent projects.
- Data centralization: Manage RFPs and supplier communications in one interface. The World Economic Forum highlighted 190% productivity gains and 45% cost reductions in digitally transformed facilities in Vietnam.
Market insights
- The U.S. accounts for 83.5% of North America’s contract manufacturing market.
- Pharma companies represent 38.7% of end-users, with bio-pharma growing fastest thanks to cell and gene therapies.
- Globally, API manufacturing makes up 70.68% of the pharma outsourcing market (2024).
- Asia-Pacific holds 38.68% of global revenue, driven by favorable regulations and government incentives.
- Outsourced manufacturing demand for GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus) surged to USD 90 billion in 2024, with CDMOs expanding drug substance, product, and fill-finish capacity.
